NCT06973421 2025-05-15
Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
6 trialsNCT02641639 2025-03-24
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics
Phase 2/3 Terminated
NCT06517433 2024-07-24
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
Phase 1 Completed
NCT06517485 2024-07-24
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
Phase 1 Completed
NCT03319628 2023-11-13
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
Phase 1/2 Active not recruiting
NCT01711970 2020-04-24
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 1/2 Completed